PhD Scientific Days 2026

Neurosciences

The Antiallodynic Effect of Selegiline Against Mononeuropathic Pain in Rats

Előadó neve

Dr. Kirchlechner-Farkas, Judit Mária

Neptune code

FWAKYZ

Előadó munkahelye

Department of Pharmacology and Pharmacotherapy

Előadó telefonszáma

06302998182

Előadó e-mail címe

kirchlechner.farkas.judit.mari@semmelweis.hu

Az előadás címe

The Antiallodynic Effect of Selegiline Against Mononeuropathic Pain in Rats

Szerző(k) neve és munkahelye

Judit Mária Kirchlechner-Farkas^1,2, Sarah K. Abbood^1,2, Imre Boldizsár^1,2, Kornél Király^1,2, Ildikó Miklya^1,2, Laszlo G Harsing Jr^1,2, Mahmoud Al-Khrasani^1,2

1: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
2: Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Neurosciences

Language of the presentation

English

Preferred session

Neurosciences

Összefoglaló szövege

Introduction: Current treatment options for neuropathic pain (NP) are not satisfactory, thus developing new drugs to solve this disorder is required. Our previous work has shown that selegiline (SELEG) has characteristics related to “enhancer” and trace amine-associated receptor (TAAR)-like effects. SELEG has been shown to produce an enhancer effect in microgram dose ranges. In addition, recent data have also reported the antiallodynic effect of TAAR ligands. Whether SELEG could elicit an antiallodynic effect mediated by the proposed mechanisms has not been elucidated.

Aim: To assess the effect of SELEG in rats with mononeuropathic pain.

Methods: Male Wistar rats (140-170 g before operation) underwent partial sciatic nerve ligation (pSNL, partial (~1/3) ligation of the n. ischiadicus under pentobarbital anaesthesia) to induce allodynia, a hallmark of NP. Tactile allodynia is indicated by a decrease in the paw withdrawal threshold (PWT) measured by a Dynamic Plantar Aesthesiometer (DPA). 7 days after pSNL, after baseline DPA measurement, rats were treated with 0.5, 0.25, 0.1 or 0.01 mg/kg SELEG or vehicle subcutaneously (n=4-6). DPA measurements were recorded 30, 60 and 120 minutes after treatment. Data are shown as mean±SEM. One-way ANOVA, followed by Dunett’s test was used to assess the significance level. All groups were compared to the vehicle.

Result: 0.5 mg/kg SELEG showed a significant antiallodynic effect at all time points.
Furthermore, SELEG at a dose of 0.01 mg/kg showed significant effect at 60 and 120 minutes. On the other hand, 0.25 mg/kg produced a significant effect only at 120 minutes.

Conclusion: SELEG can alleviate allodynia in neuropathic rats through mechanisms attributed to MAO inhibition and enhancer effect.

Limitations: The observed effect needs elucidation in the context of TAAR or other targets.

Funding: TKP2021-EGA-25

University

Semmelweis University

Supervisor

Dr. Mahmoud Al-Khrasani

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9815

Start

16:15

End

16:25